Circulating Micrornas Predict Survival of Patients with Tumors of Glial Origin
Drusco A,
P. Fadda,
Nigita G,
Fassan M,
Bottoni A,
Gardiman MP,
D. Sacchi,
Calore F,
Carosi M,
Antenucci A,
B. Casini,
Kelani H,
Pescarmona E,
Di Leva G,
Zanesi N,
Berger MS,
Croce CM
Affiliations
Drusco A
Dept. of Cancer Biology and Genetics (CBG), The Ohio State University, Columbus, OH, United States; Corresponding authors at: The John W. Wolfe Chair in Human Cancer Genetics, Institute of Genetics, Human Cancer Genetics Program, Ohio State University, Columbus, 1082 Biomedical Research Tower, 460W 12th Av., BRT, 43210, Columbus, OH, USA.
P. Fadda
CCC - Genomics Shared Resource, The Ohio State University, Columbus, OH, United States
Nigita G
Dept. of Cancer Biology and Genetics (CBG), The Ohio State University, Columbus, OH, United States
Fassan M
Dept. of Medicine (DIMED), Surgical Pathology & Cytopathology Unit, University of Padua, Italy
Bottoni A
Dept. of Cancer Biology and Genetics (CBG), The Ohio State University, Columbus, OH, United States
Gardiman MP
Dept. of Medicine (DIMED), Surgical Pathology & Cytopathology Unit, University of Padua, Italy
D. Sacchi
Dept. of Medicine (DIMED), Surgical Pathology & Cytopathology Unit, University of Padua, Italy
Calore F
Dept. of Cancer Biology and Genetics (CBG), The Ohio State University, Columbus, OH, United States
Carosi M
Dept. of Pathology, IRCCS Regina Elena National Cancer Institute, Rome, Italy
Antenucci A
Dept. of Clinical Pathology, IRCCS Regina Elena National Cancer Institute, Rome, Italy
B. Casini
Dept. of Pathology, IRCCS Regina Elena National Cancer Institute, Rome, Italy
Kelani H
Dept. of Cancer Biology and Genetics (CBG), The Ohio State University, Columbus, OH, United States
Pescarmona E
Dept. of Pathology, IRCCS Regina Elena National Cancer Institute, Rome, Italy
Di Leva G
University of Salford, School of Environment & Life Sciences, UK
Zanesi N
Dept. of Cancer Biology and Genetics (CBG), The Ohio State University, Columbus, OH, United States
Berger MS
Dept. of Neurological Surgery, University of California, San Francisco (UCSF), San Francisco, CA, USA
Croce CM
Dept. of Cancer Biology and Genetics (CBG), The Ohio State University, Columbus, OH, United States; Corresponding authors at: The John W. Wolfe Chair in Human Cancer Genetics, Institute of Genetics, Human Cancer Genetics Program, Ohio State University, Columbus, 1082 Biomedical Research Tower, 460W 12th Av., BRT, 43210, Columbus, OH, USA.
The World Health Organization has recently introduced molecular prognostic-diagnostic biomarkers in the classification of Central Nervous System (CNS) tumors. In order to characterize subclasses of tumors that cannot find a precise location in the current classification, and, or cannot be tested because of scant material, it is important to find new molecular biomarkers in tissue and, or biological fluid samples. In this study, we identified serum microRNAs that could serve as biomarkers for the diagnosis and prognosis of patients with tumors of glial origin. We retrospectively analyzed microRNA expression in the serum extracellular vesicles of patients with tumors of glial origin. Extracellular vesicles RNA was analyzed by Nanostring. qRT-PCR confirmed 6 overexpressed microRNAs: hsa-miR-4443, hsa-miR-422a, hsa-miR-494-3p, hsa-miR-502-5p, hsa-miR-520f-3p, and hsa-miR-549a. Hsa-miR-4443 was the only microRNA that showed significant differences in most comparisons. In situ hybridization (ISH), confirmed that our signature was mostly expressed in cancer cells.Importantly, hsa-miR-549a and hsa-miR-502-5p expression predicted prognosis in patients with tumors of glial origin. Although more studies are needed, we demonstrated that serum vesicles microRNA profiles are promising diagnostic and prognostic molecular biomarkers that will find an actual application in the clinical practice of CNS tumors. Keywords: microRNA, CNS tumors, Serum, Biomarkers, Diagnosis, Prognosis
